---
title: 'Liquid biopsy-based early tumor and minimal residual disease detection: New
  perspectives for cancer predisposition syndromes'
date: '2024-06-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38835740/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240605181437&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Genetic predisposition is one of the major measurable cancer risk factors.
  Affected patients have an enhanced risk for cancer and require life-long surveillance.
  However, current screening measures are mostly invasive and only available for certain
  tumor types. Particularly in hereditary cancer syndromes, liquid biopsy, in addition
  to monitoring therapy response and assessing minimal residual disease, holds great
  potential for surveillance at the precancerous stage and potentially ...
disable_comments: true
---
Genetic predisposition is one of the major measurable cancer risk factors. Affected patients have an enhanced risk for cancer and require life-long surveillance. However, current screening measures are mostly invasive and only available for certain tumor types. Particularly in hereditary cancer syndromes, liquid biopsy, in addition to monitoring therapy response and assessing minimal residual disease, holds great potential for surveillance at the precancerous stage and potentially ...